Innate Pharma SA Sales And Marketing Expense
Innate Pharma SA (IPHA) reported Sales And Marketing Expense of EUR 519.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2026-04-01
| Period end | Sales And Marketing Expense 6 month | Sales And Marketing Expense 6 month as first filed | Sales And Marketing Expense 12 month | Sales And Marketing Expense 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 519.00K EUR 20-F · filed 2026-04-01 | |||
| 2025-06-30 | 182.00K EUR 6-K · filed 2025-09-17 | |||
| 2024-12-31 | 353.00K EUR 20-F · filed 2026-04-01 | |||
| 2024-06-30 | 180.00K EUR 6-K · filed 2025-09-17 | |||
| 2023-12-31 | 368.00K EUR 20-F · filed 2026-04-01 | |||
| 2023-06-30 | 176.00K EUR 6-K · filed 2024-09-12 | |||
| 2022-12-31 | 660.00K EUR 20-F · filed 2025-04-30 | |||
| 2022-06-30 | 459.00K EUR 6-K · filed 2023-09-14 | |||
| 2021-12-31 | 472.00K EUR 20-F · filed 2024-04-04 | |||
| 2021-06-30 | 159.00K EUR 6-K · filed 2022-09-15 | 189.00K EUR 6-K · filed 2021-09-15 | ||
| 2020-12-31 | 504.00K EUR 20-F · filed 2023-04-06 | 516.00K EUR 20-F · filed 2021-04-27 | ||
| 2020-06-30 | 795.00K EUR 6-K · filed 2021-09-15 | |||
| 2019-12-31 | 592.00K EUR 20-F · filed 2022-04-04 | 629.00K EUR 20-F · filed 2020-04-24 | ||
| 2018-12-31 | 518.00K EUR 20-F · filed 2021-04-27 | |||
| 2017-12-31 | 649.00K EUR 20-F · filed 2020-04-24 |